Arcadia Biosciences Files 8-K
Ticker: RKDA · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1469443
| Field | Detail |
|---|---|
| Company | Arcadia Biosciences, Inc. (RKDA) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2024 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 9 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing
TL;DR
Arcadia Biosciences filed a routine 8-K on 12/11/24. No major news.
AI Summary
Arcadia Biosciences, Inc. filed an 8-K on December 11, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Arcadia Biosciences, Inc. to the SEC, without disclosing specific material events.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain information that suggests an immediate risk.
Key Players & Entities
- Arcadia Biosciences, Inc. (company) — Registrant
- December 11, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-37383 (identifier) — Commission File Number
- 81-0571538 (identifier) — IRS Employer Identification No.
- 5950 Sherry Lane Suite 215 (address) — Principal Executive Offices
- Dallas, Texas (location) — Principal Executive Offices Location
- 75225 (zip_code) — Principal Executive Offices Zip Code
- 214 974-8921 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits as of December 11, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is December 11, 2024.
In which U.S. state is Arcadia Biosciences, Inc. incorporated?
Arcadia Biosciences, Inc. is incorporated in Delaware.
What is the Commission File Number for Arcadia Biosciences, Inc.?
The Commission File Number for Arcadia Biosciences, Inc. is 001-37383.
What is the address of Arcadia Biosciences, Inc.'s principal executive offices?
The address of Arcadia Biosciences, Inc.'s principal executive offices is 5950 Sherry Lane Suite 215, Dallas, Texas, 75225.
Filing Stats: 2,251 words · 9 min read · ~8 pages · Grade level 17.9 · Accepted 2024-12-11 17:09:42
Filing Documents
- rkda-20241211.htm (8-K) — 60KB
- rkda-ex99_1.htm (EX-99.1) — 28KB
- rkda-ex99_1s1.jpg (GRAPHIC) — 261KB
- rkda-ex99_1s2.jpg (GRAPHIC) — 1003KB
- rkda-ex99_1s3.jpg (GRAPHIC) — 786KB
- rkda-ex99_1s4.jpg (GRAPHIC) — 883KB
- rkda-ex99_1s5.jpg (GRAPHIC) — 402KB
- rkda-ex99_1s6.jpg (GRAPHIC) — 373KB
- rkda-ex99_1s7.jpg (GRAPHIC) — 506KB
- rkda-ex99_1s8.jpg (GRAPHIC) — 407KB
- rkda-ex99_1s9.jpg (GRAPHIC) — 307KB
- rkda-ex99_1s10.jpg (GRAPHIC) — 222KB
- rkda-ex99_1s11.jpg (GRAPHIC) — 612KB
- rkda-ex99_1s12.jpg (GRAPHIC) — 461KB
- rkda-ex99_1s13.jpg (GRAPHIC) — 382KB
- rkda-ex99_1s14.jpg (GRAPHIC) — 473KB
- rkda-ex99_1s15.jpg (GRAPHIC) — 495KB
- rkda-ex99_1s16.jpg (GRAPHIC) — 374KB
- rkda-ex99_1s17.jpg (GRAPHIC) — 394KB
- rkda-ex99_1s18.jpg (GRAPHIC) — 644KB
- rkda-ex99_1s19.jpg (GRAPHIC) — 333KB
- 0000950170-24-135447.txt ( ) — 13046KB
- rkda-20241211.xsd (EX-101.SCH) — 24KB
- rkda-20241211_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 5, 2024, Arcadia Biosciences, Inc. (the "Company" or "Arcadia") issued a press release announcing that it had entered into a Securities Exchange Agreement (the "Exchange Agreement") with Roosevelt Resources, LP, a Texas limited partnership ("Roosevelt" or the "Partnership"), providing for a proposed business combination transaction (the "Transaction") between the two companies in an all-stock transaction. Arcadia and Roosevelt held a live webcast presentation at 1:30 p.m. Eastern time on December 11, 2024, to discuss the proposed Transaction. Furnished as Exhibit 99.1 hereto and incorporated herein by reference is an investor presentation that was discussed during the webcast presentation and will be used by Arcadia and Roosevelt in connection with the proposed Transaction. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act'), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing. Arcadia makes no admission as to the materiality of any information in this Current Report on Form 8-K, including Exhibit 99.1, that is required to be disclosed solely by Regulation FD. Cautionary Statement Regarding Forward-Looking Information This Current Report on Form 8-K (the "Report") contains forward-looking statements within the meaning of the safe harbor provided by Section 27A of the Securities Act, Section 21E of the Exchange Act, and the Private Securities Litigation Reform Act of 1995, about Arcadia and Roosevelt. Forward-looking statements are all statements other than statements of historical facts. The words "anticipate," "believe," "ensure," "expect," "if," "in
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Investor Presentation dated December 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCADIA BIOSCIENCES, INC. Date: December 11, 2024 By: /s/ Mark Kawakami Mark Kawakami, Chief Financial Officer